A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Servier
Pfizer
Eli Lilly and Company
Bristol-Myers Squibb
Genmab
Actuate Therapeutics Inc.
Revolution Medicines, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Artios Pharma Ltd
Pfizer
Memorial Sloan Kettering Cancer Center
Genfleet Therapeutics (Shanghai) Inc.
Incyte Corporation
Bristol-Myers Squibb
Jazz Pharmaceuticals
Incyte Corporation
Toray Industries, Inc
Trishula Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
Esperas Pharma Inc.
IGM Biosciences, Inc.
Eli Lilly and Company
Taiho Pharmaceutical Co., Ltd.
Cantargia AB
Canadian Cancer Trials Group
Cantargia AB
Northwestern University
Oslo University Hospital
Eli Lilly and Company
Incyte Corporation
Wake Forest University Health Sciences
Benaroya Research Institute
Gilead Sciences
TG Therapeutics, Inc.
Masonic Cancer Center, University of Minnesota
Northwestern University
University of Miami
Vejle Hospital
University of Southern California
Seoul National University Bundang Hospital
National Cancer Institute (NCI)
Vejle Hospital
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Royal Marsden NHS Foundation Trust
National Cancer Institute (NCI)
National Cancer Institute (NCI)